InfaCare 64,185-205

Principal Investigator: JulieShakib
Keywords: Stannsoporfin , Pediatrics , Hyperbilirubinemia Department: Pediatric Administration
IRB Number: 00066249 Co Investigator: Michael Spigarelli
Specialty: Pediatrics, General
Sub Specialties:
Recruitment Status: Not yet recruiting

Contact Information

Priscilla Cowan
priscilla.rosen@hsc.utah.edu
8012133401

Brief Summary

The objectives of this follow up study are to evaluate the long-term effects of stannsoporfin (Stanate) on the health, growth, and development of patients who received a single dose of stannsoporfin with PT used to treat hyperbilirubinemia compared with patients in the control (placebo plus PT) group in clinical trial 64,185-204.

Inclusion Criteria

Patients will meet the following entry criteria for study eligibility:

• Patients who have received IMP (stannsoporfin or placebo) in clinical trial 64,185-204

• Written informed consent provided by parents/guardians

Exclusion Criteria

none